Optimism is important, especially if you're not going to to sell out and walk away from this company. It is also important to realize the risk of delays. Every day researchers are working on treatments and cures for cancer and every day they are getting closer to making BPTH irrelevant. As good as the data has been, it only matters if there isn't something better.
Story time, GenMark Diagnostics announced 5 years ago they were making a test platform and product to compete and overshadow BioFire Diagnostics. They ran into delays in development, scale-up, and FDA clearances. They still do not have an FDA cleared product that can compete with BioFire. In that time window, BioFire identified the threat and opportunity, developed a new platform, got FDA clearance, and expanded their platform utility. They are selling a useable product to all of the customers GenMark is selling promises to. Guess who is winning and doing more business in a month than GenMark does in 6 months?
BPTH has been promising and failing for too long. The window of opportunity is closing and if they don't act fast they might end up with a product that no one wants or needs. It doesn't matter how good their data is and how successful their clinical studies have been. BPTH needs a new CEO who is competent about drug development and the pharmaceutical industry. Peter is not that CEO!
In regards to MD Anderson being involved. Of course they are, they get paid regardless of whether this drug is successful or not, same with all the cancer centers involved. While I believe they are interested in good science and advancing clinical care, performing clinical studies for biotech and pharmaceutical companies is BIG money for theses institutions!
